# OnCo record keynote-921 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-921/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-921", "NCT03834506" ;
  schema:name "KEYNOTE-921"@en ;
  schema:alternateName "KEYNOTE-921"@en, "MK-3475-921"@en ;
  schema:description "Adding pembrolizumab to chemotherapy for advanced prostate cancer did not work, and it added side effects and lung inflammation."@en ;
  schema:url <https://onco.cc/trials/keynote-921/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03834506>, <https://doi.org/10.1200/JCO-24-01283>, <https://doi.org/10.1016/j.euo.2025.02.015> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/qol-pro/> ;
  onco:trials <https://onco.cc/trials/keynote-641/>, <https://onco.cc/trials/keynote-991/>, <https://onco.cc/trials/imbassador250/> .